Oracea (40mg doxycycline)

Oracea is a once per day 40mg (30mg immediate release and 10mg delayed release) doxycycline treatment for the papules and pustles of rosacea. Galderma promote Oracea as superior to 50mg a day of generic doxycycline because Oracea is a low enough dose to be promoted as an `anti-inflamatory only’ treatment and not suffering from potential problems of higher doses of antibiotics.

Be sure to checkout the Oracea User Reviews.

Recent Rosacea Blog Posts

An interesting note from the detailed interim judgement in the ongoing patent dispute between Galderma and Mylan. As part of the proceedings Mylan looked at the on-going Oracea sales and projected that Galderma can expect to receive around $260 million in 2011. MYLAN PHARMACEUTICALS INC., v.  GALDERMA LABORATORIES, L.P.; et. al. Mylan projected that Oracea’s […]

Continue Reading

Mylan Violates The Chang Patent for Oracea

Another step in the ongoing battle between Galderma and Mylan over the right to manufacture generic Oracea. A judge has declared that Mylan infringes 1 of the patents that protects Oracea from generic copies. Some History In July 2010, Mylan was banned from selling generic Oracea, despite having regulatory approval, pending the outcome of the […]

Continue Reading

Metrogel, Finacea and Oracea are Best for Rosacea

A systematic review of the available rosacea research confirms that Metrogel, Finacea and Oracea are effective for moderate to severe rosacea. One study further found cyclosporine 0.05% ophthalmic emulsion effective for ocular rosacea. This review looked at the published results of 58 trials to note bias and construct a high level summary of the results. […]

Continue Reading

Galderma blocking Impax making Generic Oracea

The last we heard from Impax Laboratories was in late 2009 when they had filed an Abbreviated New Drug  Application (ANDA 91-447) to produce a generic version of Oracea. A recent filing in  Delaware shows Galderma attempting to block the production of Generic Oracea by invoking the protection of Patent 7,749,532. Galderma claim that this […]

Continue Reading

The Vitligo and Pigmentation Institute of Southern California is hosting part of the trial to evaluate Rosacea-related Inflammatory Biochemical Markers in Adult Skin When Treated With Oracea  vs Placebo. This trial is looking to prove changes in inflammatory markers like the peptide LL-37 and the MMP family match the improvement seen when taking Oracea. The […]

Continue Reading

 

Top

Subscribe to Rosacea News

Enter your email address to receive the latest news about rosacea in your inbox.